Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
Go back to Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress| COGENT (NASDAQ: COGT) | Delayed: 35.84 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.84 | 52 Week High | $5.57 | |||
| Open | $35.84 | 52 Week Low | $2.90 | |||
| Day High | $35.84 | P/E | 162.91 | |||
| Day Low | $35.84 | EPS | $0.22 | |||
| Volume | 21 | |||||
